SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-067710
Filing Date
2022-06-02
Accepted
2022-06-02 17:15:44
Documents
12
Period of Report
2022-05-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2217462d1_8k.htm   iXBRL 8-K 27208
  Complete submission text file 0001104659-22-067710.txt   199940

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ymab-20220530.xsd EX-101.SCH 3024
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ymab-20220530_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ymab-20220530_pre.xml EX-101.PRE 22589
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2217462d1_8k_htm.xml XML 3596
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 22991958
SIC: 2834 Pharmaceutical Preparations